What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Immune system
His scientific interests lie mostly in Immunology, Immunotherapy, Melanoma, Immune checkpoint and Cancer research.
His research investigates the connection between Immunology and topics such as Cytotoxic T cell that intersect with problems in T cell and Myeloid-derived Suppressor Cell.
His work deals with themes such as Endogenous retrovirus and Immunogenicity, which intersect with Immunotherapy.
Taha Merghoub combines subjects such as MEK inhibitor, MAPK/ERK pathway, V600E and Checkpoint Blockade Immunotherapy with his study of Melanoma.
His research in Immune checkpoint intersects with topics in Interferon, Interferon type I and Cancer immunotherapy.
His Cancer research research is multidisciplinary, incorporating perspectives in Transcription, Repressor and Innate immune system, Innate lymphoid cell.
His most cited work include:
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (4293 citations)
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma (2586 citations)
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (1503 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Cancer research, Immunology, Immune system, Immunotherapy and T cell.
Taha Merghoub studies Cancer research, namely Melanoma.
Immunology is closely attributed to Cytotoxic T cell in his work.
His Immunotherapy study combines topics from a wide range of disciplines, such as Lung cancer, Myeloid-derived Suppressor Cell, KRAS and Immunogenicity.
His T cell research incorporates themes from Priming and Cell biology.
His Immune checkpoint study deals with Oncolytic virus intersecting with Intratumoral Therapy.
He most often published in these fields:
- Cancer research (53.47%)
- Immunology (38.61%)
- Immune system (34.65%)
What were the highlights of his more recent work (between 2019-2021)?
- Cancer research (53.47%)
- Immunotherapy (32.34%)
- Immune checkpoint (26.07%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer research, Immunotherapy, Immune checkpoint, Immune system and T cell.
His Cancer research research focuses on Melanoma in particular.
Taha Merghoub interconnects Cancer cell and Vaccinia in the investigation of issues within Immune checkpoint.
His work on CD8 as part of general Immune system study is frequently linked to Population, therefore connecting diverse disciplines of science.
His research on CD8 concerns the broader Immunology.
The T cell study combines topics in areas such as Innate immune system, Antigen, Immunogenicity and Cancer immunotherapy.
Between 2019 and 2021, his most popular works were:
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity (57 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
Immunotherapy, Cancer research, Blockade, CD8 and Immune system are his primary areas of study.
The various areas that he examines in his Immunotherapy study include T cell, Lung cancer, Oncology and Immunogenicity.
His Cancer research study incorporates themes from Tumor microenvironment, Downregulation and upregulation, Antigen and Mutation.
His Blockade research includes themes of Neoadjuvant therapy, Major Pathologic Response, Carcinoma, T-cell receptor and Biomarker.
Specifically, his work in Immune system is concerned with the study of Immune checkpoint.
His Immune checkpoint study combines topics in areas such as Non small cell, Cell and Long term response.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
